WO2004014293A3 - Combination of anti-muscarinic agents and non-glucocorticoid steroids - Google Patents

Combination of anti-muscarinic agents and non-glucocorticoid steroids Download PDF

Info

Publication number
WO2004014293A3
WO2004014293A3 PCT/US2003/018967 US0318967W WO2004014293A3 WO 2004014293 A3 WO2004014293 A3 WO 2004014293A3 US 0318967 W US0318967 W US 0318967W WO 2004014293 A3 WO2004014293 A3 WO 2004014293A3
Authority
WO
WIPO (PCT)
Prior art keywords
combination
muscarinic agents
glucocorticoid steroids
salts
glucocorticoid
Prior art date
Application number
PCT/US2003/018967
Other languages
French (fr)
Other versions
WO2004014293A2 (en
Inventor
Jonathan W Nyce
Cynthia B Robinson
Original Assignee
Epigenesis Pharmaceuticals Inc
Jonathan W Nyce
Cynthia B Robinson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Epigenesis Pharmaceuticals Inc, Jonathan W Nyce, Cynthia B Robinson filed Critical Epigenesis Pharmaceuticals Inc
Priority to MXPA04012410A priority Critical patent/MXPA04012410A/en
Priority to AU2003276837A priority patent/AU2003276837B2/en
Priority to BR0311747-2A priority patent/BR0311747A/en
Priority to EP03784741A priority patent/EP1511500A4/en
Priority to CA002487399A priority patent/CA2487399A1/en
Priority to JP2004527571A priority patent/JP2006504666A/en
Publication of WO2004014293A2 publication Critical patent/WO2004014293A2/en
Publication of WO2004014293A3 publication Critical patent/WO2004014293A3/en
Priority to IL16509304A priority patent/IL165093A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Abstract

A pharmaceutical or veterinary composition comprises a non-corticosteroids, and/or salts thereof, and an antimuscarinic (anti-cholinergic) agent, and/or pharmaceutically or veterinarilly acceptable salts thereof. The composition is provided in carious formulations and in the form of a kit. The products of this patent are useful in the prophylaxis and treatment of various respiratory, lung and malignant diseases.
PCT/US2003/018967 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids WO2004014293A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
MXPA04012410A MXPA04012410A (en) 2002-06-12 2003-06-12 Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s).
AU2003276837A AU2003276837B2 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
BR0311747-2A BR0311747A (en) 2002-06-12 2003-06-12 Pharmaceutical composition, single or multiple dose form of composition, kit, and method for treating disease
EP03784741A EP1511500A4 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
CA002487399A CA2487399A1 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids
JP2004527571A JP2006504666A (en) 2002-06-12 2003-06-12 Compositions, formulations and kits for treating respiratory and pulmonary diseases with dehydroepiandrosterone steroids and antimuscarinic agents
IL16509304A IL165093A0 (en) 2002-06-12 2004-11-08 Composition, formulations and kit for treatment ofrespiatory and lung disease with dehydroepiandros terone(s)steroid and an anti-muscarinic agent(s)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38817002P 2002-06-12 2002-06-12
US60/388,170 2002-06-12

Publications (2)

Publication Number Publication Date
WO2004014293A2 WO2004014293A2 (en) 2004-02-19
WO2004014293A3 true WO2004014293A3 (en) 2004-09-23

Family

ID=31715648

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2003/018967 WO2004014293A2 (en) 2002-06-12 2003-06-12 Combination of anti-muscarinic agents and non-glucocorticoid steroids

Country Status (10)

Country Link
EP (1) EP1511500A4 (en)
JP (1) JP2006504666A (en)
KR (1) KR20060011783A (en)
CN (2) CN101700247A (en)
AU (1) AU2003276837B2 (en)
BR (1) BR0311747A (en)
CA (1) CA2487399A1 (en)
IL (1) IL165093A0 (en)
MX (1) MXPA04012410A (en)
WO (1) WO2004014293A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050026882A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease
US7923455B2 (en) * 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
MX2008001506A (en) * 2005-08-06 2008-04-07 Boehringer Ingelheim Int Use of tiotropium salts in the treatment of severe persistant asthma.
WO2007109142A2 (en) * 2006-03-17 2007-09-27 Oregon Health & Science University M3 muscarinic receptor antagonists for treating tumors
PL2148691T3 (en) * 2007-02-05 2015-12-31 Apellis Pharmaceuticals Inc Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
AU2015201037C1 (en) * 2009-05-29 2017-07-27 Pearl Therapeutics, Inc. Respiratory delivery of active agents
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
RU2696582C2 (en) 2013-03-15 2019-08-05 Перл Терапьютикс, Инк. Methods and systems for conditioning disperse crystalline materials
WO2019182745A1 (en) 2018-03-19 2019-09-26 Bryn Pharma, LLC Epinephrine spray formulations
EP3847141A1 (en) * 2018-09-07 2021-07-14 Allied Mineral Products, LLC Dry refractory compositions with reduced levels of respirable crystalline silica

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429187A1 (en) * 1989-10-26 1991-05-29 ELAN CORPORATION, Plc Enhanced bioavailability adsorbates
US6087351A (en) * 1995-02-24 2000-07-11 East Carolina University Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone
US6150348A (en) * 1993-03-09 2000-11-21 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270305A (en) * 1989-09-08 1993-12-14 Glaxo Group Limited Medicaments
AU6048694A (en) * 1992-12-09 1994-07-04 Paul D. Jager Stabilized medicinal aerosol solution formulations
US5859000A (en) * 1995-06-07 1999-01-12 University Of Utah Research Foundation Method for reducing mast cell mediated allergic reactions
DE50103551C5 (en) * 2000-10-12 2014-08-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg NEW TIOTROPIUM-CONTAINING INHALATION POWDER
AU2002303425A1 (en) * 2001-04-24 2002-11-05 Epigenesis Pharmaceuticals, Inc. Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
AU2002303427A1 (en) * 2001-04-24 2002-11-05 East Carolina University Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
US20030216329A1 (en) * 2001-04-24 2003-11-20 Robinson Cynthia B. Composition, formulations & kit for treatment of respiratory & lung disease with dehydroepiandrosterone(s) steroid & an anti-muscarinic agent(s)
US20050038004A1 (en) * 2003-07-31 2005-02-17 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anticholinergic bronchodilator for treatment of asthma or chronic obstructive pulmonary disease

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0429187A1 (en) * 1989-10-26 1991-05-29 ELAN CORPORATION, Plc Enhanced bioavailability adsorbates
US6150348A (en) * 1993-03-09 2000-11-21 University Of Utah Research Foundation Methods for preventing progressive tissue necrosis, reperfusion injury, bacterial translocation and adult respiratory distress syndrome
US6087351A (en) * 1995-02-24 2000-07-11 East Carolina University Method for reducing adenosine levels with a dehydroepiandrosterone and optionally a ubiquinone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9463161B2 (en) 2009-05-29 2016-10-11 Pearl Therapeutics, Inc. Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems

Also Published As

Publication number Publication date
KR20060011783A (en) 2006-02-03
CN101700247A (en) 2010-05-05
AU2003276837B2 (en) 2006-07-20
AU2003276837A1 (en) 2004-02-25
BR0311747A (en) 2005-06-07
EP1511500A4 (en) 2009-04-29
EP1511500A2 (en) 2005-03-09
AU2003276837A2 (en) 2004-02-25
MXPA04012410A (en) 2005-10-19
CN1674918A (en) 2005-09-28
CA2487399A1 (en) 2004-02-19
IL165093A0 (en) 2005-12-18
WO2004014293A2 (en) 2004-02-19
JP2006504666A (en) 2006-02-09

Similar Documents

Publication Publication Date Title
AU2002303427A1 (en) Compositions and formulations with a non-glucocorticoid steroid and/or a ubiquinone and kit for treatment of respiratory and lung disease
WO2002085296A3 (en) Composition, formulations and kit for treatment of respiratory and lung disease with non-glucocorticoid steroids and/or ubiquinone and a bronchodilating agent
WO2004037807A3 (en) Medicinal arylethanolamine compounds
CA2392879A1 (en) A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders
YU71901A (en) NOVEL MEDICAMENT COMPOSITIONS, BASED ON ANTICHOLINERGICALLY EFFECTIVE COMPOUNDS AND beta-MIMETICS
IL168279A (en) Use of liposomal aminoglycoside formulation in the manufacture of a medicament for treating or ameliorating pulmonary infection
IL204947A0 (en) Phenylacetamido-thiazole derivatives, process for their preparation and their use in the manufacture of medicaments, pharmaceutical compositions and kits comprising them
MY148125A (en) Compounds
WO2004014293A3 (en) Combination of anti-muscarinic agents and non-glucocorticoid steroids
WO2003087049A3 (en) Pharmaceutical combinations containing heterocyclic compounds and a novel anticholinergic agent
AU2002305236A1 (en) Composition, formulations and kits for treatment of respiratory and lung disease with anti-sense oligonucleotides and a bronchodilating agent
WO2002088100A3 (en) Deuterated 3-piperidinopropiophenone and medicaments containing said compounds
WO2005011614A8 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an anti-ige antibody for treatment of asthma or chronic obstructive pulmonary disease
WO2003066597A3 (en) Guanidino compounds
IL150817A0 (en) Pyrrole-type compounds, compositions, and methods for treating cancer or viral diseases
EP1778209B8 (en) Methods and compositions for oral delivery of fts
AU2003290015A1 (en) Mastitis treatment
SE9902935D0 (en) Pharmaceutical compositions
TWI347845B (en) Pharmaceutical compositions,combinations,and kits for the treatment of respiratory diseases and use of the same
WO2006079910A3 (en) 0-(3-piperidino-2hydroxypropyl)nicotinic amixodime for treating lesions in the oral cavity
WO2005011604A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with an antihistamine for treatment of asthma or chronic obstructive pulmonary disease
WO2002069979A3 (en) Pharmaceutical formulation comprising r-salmeterol and fluticasone propionate
WO2005011602A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
WO2005011595A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a leukotriene receptor antagonist for treatment of asthma or chronic obstructive pulmonary disease
WO2005011616A3 (en) Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a cromone for treatment of asthma or chronic obstructive pulmonary disease

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NI NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 165093

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 3481/DELNP/2004

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2003276837

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2003784741

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2487399

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004527571

Country of ref document: JP

Ref document number: PA/a/2004/012410

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 1020047020226

Country of ref document: KR

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 20038193000

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2003784741

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1020047020226

Country of ref document: KR